Summary
Central nervous system (CNS) infection continues to be a significant cause of morbidity and mortality in children. Nonfatal CNS infections produce neurological and audiological sequelae in 5 to 30% of cases. Current case fatality rates in bacterial meningitis are between 3 and 7% in infants and children, increasing to approximately 30% in newborns.
Important advances include improved understanding of the pathophysiology of bacterial meningitis and of therapeutic interventions, such as steroids, that may modulate the inflammatory response and improve clinical outcome. Another advance has been the introduction of third generation cephalosporins such as cefotaxime, ceftriaxone and ceftazidime. The agents penetrate well into the CNS and are active against Gram-negative bacilli (including Escherichia coli, Klebsiella spp., Salmonella spp.) and other organisms such as Pseudomonas spp. Other advances include techniques for the rapid diagnosis of bacterial meningitis, and the prophylactic measures such as immunisation against Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis.
Similar content being viewed by others
References
Arguedas AG, Wehrle P. New concepts for antimicrobial use in central nervous system infections. Seminars in Pediatric Infectious Diseases 2: 36–42, 1991
Ascher DP, Wilson S, Mendiola J, Fischer GW. Group B streptococcal latex agglutination testing in neonates. Journal of Pediatrics 119: 458–461, 1991
Black SV, Shinefield HR, Lampert D, Fireman B, Hiatt RA, et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. Pediatric Infectious Diseases Journal 10: 90–96, 1991
Committee on Infectious Diseases, American Academy of Pediatrics. Dexamethasone therapy for bacterial meningitis in infants and children. Pediatrics 86: 130–132, 1990
Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. New England Journal of Medicine 311: 869–874, 1984
Francke EL, Neu HC. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. American Journal of Medicine 71: 435–442, 1981
Greenlee JE. Approach to diagnosis of meningitis. Cerebrospinal fluid evaluation. Infectious Diseases Clinics of North America 4: 583–593, 1990
Guggenbichler JP, Kofler J, Allerger F. Influence of third-generation cephalosporins on aerobic intestinal flora. Infection 13 (Suppl. 1): 137–139, 1985
Kaplan SL, Feigin RD. Rapid identification of the invading microorganism. Pediatric Clinics of North America 27: 783–803, 1980
Kaplan SL, Feigin RD. Clinical presentation, prognostic factors and diagnosis of bacterial meningitis. In Sands MA, et al. (Eds) Bacterial meningitis, pp. 83–94, Churchill Livingstone, New York, 1985
Klein J, Marcy SM. Bacterial sepsis and meningitis. In Remington J, Klein SM (Eds) Infectious diseases of the fetus and newborn infant, 3rd ed., pp. 601–656, Saunders, Philadelphia, 1990
Konradsen HB, Henrichsen J. Pneumococcal infections in splenectomised children are preventable. Acta Paediatrica Scandinavica 80: 423–427, 1991
Mustafa MM, Lebel MH, Ramilo O, Olsen KD, Reisch JS, et al. Correlation of interleukin-1B and cachectin concentration in cerebrospinal fluid and outcome from bacterial meningitis. Journal of Pediatrics 11: 208–213, 1989
Mustafa MM, Ramilo O, Saez-Llorens X, Olsen KD, Magness RR, et al. Cerebrospinal fluid prostaglandins interleukin-1B, and tumor necrosis factor in bacterial meningitis. American Journal of Diseases of Children 144: 883–887, 1990
Neu HC. Cephalosporins in the treatment of meningitis. Drugs 34 (Suppl. 2): 135–153, 1987
Odio CM, Faingezicht I, Paris M, Nassar M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. New England Journal of Medicine 324: 1525–1531, 1991
Odio CM, Faingezicht I, Salas JL, Guevara J, Mohs E, et al. Cefotaxime vs conventional therapy for the treatment of bacterial meningitis of infants and children. Pediatric Infectious Diseases Journal 5: 402–407, 1986
Ramilo O, Mustafa MM, Porter J, Saez-Llorens X, Mersola J, et al. Detection of interleukin IB but not tumor necrosis factor alfa in cerebrospinal fluid of children with aseptic meningitis. American Journal of Diseases of Children 144: 349–352, 1990b
Ramilo O, Saez-Llorens X, Mertsola J, Jafari H, Olsen KD, et al. Tumor necrosis factor alfa/cachectin and interleukin IB initiate meningeal inflammation. Journal of Experimental Medicine 172: 497–507, 1990a
Rodriguez WJ, Puig JR, Khan WN, Feris J, Gold BG, et al. Ceftazidime vs standard therapy for pediatric meningitis: therapeutic, pharmacologic and epidemiologic observations. Pediatric Infectious Diseases Journal 5: 408–415, 1986
Saez-Llorens X, McCracken Jr GH. Bacterial meningitis in neonates and children. Infectious Diseases Clinics of North America 4: 623–644, 1990
Saez-Llorens X, Ramilo O, Mustafa MM, Mertsola J, McCracken Jr GH. Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. Journal of Pediatrics 116: 671–684, 1990
Schlech WF, Ward JI, Band JD, Hightower A, Fraser DW, et al. Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance study. Journal of the American Medical Association 253: 1749–1754, 1985
Solórzano SF, Arredondo JL, Calderón JE. Meningoencefalitis purulenta neonatal. In Calderón JE, et al. (Eds) Infectología Perinatal. 2a ed. Ed. Trillas, pp. 326–334, Mexico, 1991
Syrogiannopoulos GA, Hansen EJ, Erwin RS, Munford RS, Rutledge J, et al. Haemophilus influenzae type B lipooligosaccharide induces meningeal inflammation. Journal of Infectious Diseases 157: 237–244, 1988
Tunkel AR, Wispelwey B, Scheid WM. Bacterial meningitis: recent advances in pathophysiology and treatment. Annals of Internal Medicine 112: 610–623, 1990
Tuomanem E. Molecular mechanisms of inflammation in experimental pneumococcal meningitis. Pediatric Infectious Disease Journal 6: 1146–1149, 1987
Turner RB, Cimino CO, Sullivan BJ. Prospective comparison of the immune response of infants to three Haemophilus influenzae type b vaccines. Pediatric Infectious Disease Journal 10: 108–112, 1991
Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV, et al. Bacterial meningitis in the United States 1986: report of a multistate surveillance study. Journal of Infectious Diseases 162: 1316–1323, 1990
Wispelway B, Tunkel AR, Scheid WM. Bacterial meningitis in adults. Infectious Diseases Clinics of North America 4: 645–659, 1990
Wood M. Acute purulent meningitis. In Wood M & Anderson M (Eds) Neurological infections, Vol. 16, pp. 49–133, WB Saunders Company, London, 1988
Word BM, Klein JO. Therapy of bacterial sepsis and meningitis in infants and children: 1989 poll of directors of programs in pediatric infectious diseases. Pediatric Infectious Disease Journal 8: 635–637, 1989
Yogev R, Shulman ST, Chadwick EG, Davis AT, Glosowski W. Once daily ceftriaxone for central nervous system infections and other serious pediatric infections. Pediatric Infectious Disease Journal 5: 298–303, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arredondo-García, JL., Ortiz-Ibarra, F.J., Figueroa-Damian, R. et al. Current Concepts in Acute Purulent Meningitis. Drug Invest 4 (Suppl 2), 18–25 (1992). https://doi.org/10.1007/BF03258353
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258353